Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States

Blood

Volumn 127, Issue 20, 2016, Pages 2481-2488

  Flood, Veronica H ^a,b,c   Christopherson, Pamela A ^c   Gill, Joan Cox ^a,b,c   Friedman, Kenneth D ^a,c   Haberichter, Sandra L ^a,b,c   Bellissimo, Daniel B ^c   Udani, Rupa A ^c   Dasgupta, Mahua ^a   Hoffmann, Raymond G ^a   Ragni, Margaret V ^d   Shapiro, Amy D ^e   Lusher, Jeanne M ^f   Lentz, Steven R ^g   Abshire, Thomas C ^a,b,c,h   Leissinger, Cindy ⁱ   Hoots, W Keith ^j   Manco Johnson, Marilyn J ^k   Gruppo, Ralph A ^l   Boggio, Lisa N ^m   Montgomery, Kate T ⁿ   Goodeve, Anne C ^o   James, Paula D ^p   Lillicrap, David ^p   Peake, Ian R ^o   Montgomery, Robert R ^a,b,c   more..

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Children's Hospital of Wisconsin   (United States)

^c BLOOD RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^f CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^k Mountain States Regional Hemophilia and Thrombosis Center   (United States)

^l CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^m RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁿ LABORATORY FOR MOLECULAR MEDICINE   (United States)

^o UNIVERSITY OF SHEFFIELD   (United Kingdom)

^p QUEEN S UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RISTOCETIN; VON WILLEBRAND FACTOR; VON WILLEBRAND ANTIGEN;

ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENETIC VARIATION; HUMAN; LABORATORY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; UNITED STATES; VON WILLEBRAND DISEASE; ADOLESCENT; BLOOD; BLOOD CLOTTING TEST; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; COMPARATIVE STUDY; DNA SEQUENCE; GENETICS; HEMORRHAGE; MULTICENTER STUDY; QUESTIONNAIRE; VON WILLEBRAND DISEASE, TYPE 1; YOUNG ADULT;

ADOLESCENT; BLOOD COAGULATION TESTS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENETIC VARIATION; HEMORRHAGE; HUMANS; MALE; PHENOTYPE; SEQUENCE ANALYSIS, DNA; SURVEYS AND QUESTIONNAIRES; UNITED STATES; VON WILLEBRAND DISEASE, TYPE 1; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84974556876     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-673681     Document Type: Article

References (46)

1. Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010;8(1):213-216.
2. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69(2):454-459.
3. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123(6):893-898.
4. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood. 2003;101(6):2089-2093.
5. Sadler JE. Slippery criteria for von Willebrand disease type 1. J Thromb Haemost. 2004;2(10):1720-1723.
6. Rydz N, James PD. The evolution and value of bleeding assessment tools. J Thromb Haemost. 2012;10(11):2223-2229.
7. Ingerslev J. A sensitive ELISA for von Willebrand factor (vWf:Ag). Scand J Clin Lab Invest. 1987;47(2):143-149.
8. Howard MA, Sawers RJ, Firkin BG. Ristocetin: a means of differentiating von Willebrand's disease into two groups. Blood. 1973;41(5):687-690.
9. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171-232.
10. Tosetto A, Rodeghiero F, Castaman G, et al. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost. 2007;5(4):715-721.
11. Quiroga T, Goycoolea M, Belmont S, et al. Quantitative impact of using different criteria for the laboratory diagnosis of type 1 von Willebrand disease. J Thromb Haemost. 2014;12(8):1238-1243.
12. Cumming A, Grundy P, Keeney S, et al; UK Haemophilia Centre Doctors' Organisation. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost. 2006;96(5):630-641.
13. James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood. 2007;109(1):145-154.
14. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007;109(1):112-121.
15. Rodeghiero F, Tosetto A, Abshire T, et al; ISTH/SSC Joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063-2065.
16. Flood VH, Gill JC, Morateck PA, et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010;116(2):280-286.
17. Simone JV, Vanderheiden J, Abildgaard CF. A semiautomatic one-stage factor 8 assay with a commercially prepared standard. J Lab Clin Med. 1967;69(4):706-712.
18. Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood. 2012;119(19):4543-4553.
19. Flood VH, Schlauderaff AC, Haberichter SL, et al; Zimmerman Program Investigators. Crucial role for the VWF A1 domain in binding to type IV collagen. Blood. 2015;125(14):2297-2304.
20. Flood VH, Gill JC, Morateck PA, et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman program for the molecular and clinical biology of VWD. Blood. 2011;117(6):e67-e74.
21. Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J; Subcommittee on von Willebrand factor. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(7):1345-1350.
22. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood. 2006;108(10):3344-3351.
23. Bellissimo DB, Christopherson PA, Flood VH, et al. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood. 2012;119(9):2135-2140.
24. Askree SH, Chin EL, Bean LH, Coffee B, Tanner A, Hegde M. Detection limit of intragenic deletions with targeted array comparative genomic hybridization. BMC Genet. 2013;14:116.
25. Xue Y, Ankala A, Wilcox WR, Hegde MR. Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing. Genet Med. 2015;17(6):444-451.
26. Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008;111(10):4979-4985.
27. Flood VH, Christopherson PA, Bellissimo DB, et al. Spectrum of type 2 von Willebrand disease in the Zimmerman program [abstract]. Blood. 2014;124(21). Abstract 472.
28. Elbatarny M, Mollah S, Grabell J, et al; Zimmerman Program Investigators. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia. 2014;20(6):831-835.
29. Flood VH, Lederman CA, Wren JS, et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost. 2010;8(6):1431-1433.
30. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691-1695.
31. Sanders YV, Giezenaar MA, Laros-van Gorkom BA, et al; WiN study group. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost. 2014;12(7):1066-1075.
32. Rydz N, Grabell J, Lillicrap D, James PD. Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease. Haemophilia. 2015;21(5):636-641.
33. Kitchen S, Jennings I, Woods TA, Kitchen DP, Walker ID, Preston FE. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost. 2006;32(5):492-498.
34. Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost. 2006;32(5):485-491.
35. Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thromb Res. 1989;53(4):387-394.
36. Rydz N, Swystun LL, Notley C, et al. The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood. 2013;121(26):5228-5237.
37. Sanders YV, van der Bom JG, Isaacs A, et al; WiN Study Group. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease. J Thromb Haemost. 2015;13(6):956-966.
38. Desch KC, Ozel AB, Siemieniak D, et al. Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association. Proc Natl Acad Sci USA. 2013;110(2):588-593.
39. Yadegari H, Driesen J, Pavlova A, Biswas A, Hertfelder HJ, Oldenburg J. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients. Thromb Haemost. 2012;108(4):662-671.
40. Bowman M, Mundell G, Grabell J, et al. Generation and validation of the condensed MCMDM-1VWD bleeding questionnaire for von Willebrand disease. J Thromb Haemost. 2008;6(12):2062-2066.
41. Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood. 2008;111(8):3998-4003.
42. Tosetto A, Castaman G, Rodeghiero F. Bleeders, bleeding rates, and bleeding score. J Thromb Haemost. 2013;11(suppl 1):142-150.
43. Graf L, Moffat KA, Carlino SA, et al. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin. Int J Lab Hematol. 2014;36(3):341-351.
44. Christopherson PA, Flood VH, Friedman KD, Gill JC, Haberichter SL, Montgomery RR. Improved diagnosis of VWD in affected family members using the ISTH bleeding score. J Thromb Haemost. 2014;12(suppl 1):95.
45. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4(4):766-773.
46. Federici AB, Bucciarelli P, Castaman G, et al. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood. 2014;123(26):4037-4044.